Back to News
Market Impact: 0.3
Bioventus Reports Higher Q3 Profit, Cuts 2026 Sales Outlook; Stock Down
Source: Nasdaq
Corporate EarningsCorporate Guidance & OutlookHealthcare & BiotechCompany Fundamentals
Bioventus reported third-quarter revenue growth, driven by its pain treatments business, but lowered its full-year 2026 sales guidance. The article provides no revenue figures or revised guidance amount.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.20
Ticker Sentiment
BVS-0.40
More News
- Binance co-CEO Richard Teng says hackers used fake job interviews, AI tool to steal $6.3 billion in crypto 108511116
- AMD stock jumps 7% on earnings as data center revenue nearly doubles
- Marvell Technology could plunge on latest multibillion-dollar acquisition
- Disney Plans Thousands of Layoffs Companywide
- AMD rides data center riches to ‘largest and most profitable’ quarter in history
- AMD’s OpenAI, Meta chip deals trigger $1 billion quarterly charge